XENE logo

Xenon Pharmaceuticals Inc. (XENE)

$39.17

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on XENE

Market cap

$3.79B

EPS

-4.74

P/E ratio

--

Price to sales

470.52

Dividend yield

--

Beta

0.105805

Price on XENE

Previous close

$37.68

Today's open

$37.80

Day's range

$37.15 - $39.21

52 week range

$33.38 - $72.66

Profile about XENE

CEO

Ian Mortimer

Employees

370

Headquarters

Burnaby, BC

Exchange

NASDAQ Global Market

Shares outstanding

96840432

Issue type

Common Stock

XENE industries and sectors

Healthcare

Biotechnology & Life Sciences

News on XENE

Xenon to Present at Upcoming Investor Conferences

VANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at four upcoming investor conferences in the fourth quarter of 2026.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Xenon to Report Q3 2026 Financial Results on November 9, 2026

VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Monday, November 9, 2026. Company Presentation Details: Date: Monday, November 9, 2026 Time: 4:30pm EST (2:30pm PCT) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID: 8984105 A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to nine new non-officer employees consisting of an aggregate of 24,250 share options and 14,250 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of October 29, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

news source

GlobeNewsWire • Oct 30, 2026

news preview

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

XEN1701 achieved target profile, including desired Na V 1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascular effects XEN1120 achieved plasma levels predictive of analgesic effects based on preclinical modeling and was generally well-tolerated New preclinical data in cynomolgus monkeys demonstrated significant reductions in capsaicin-evoked heat pain for Na V 1.7 and K V 7 compounds Phase 2 proof-of-concept studies assessing XEN1701 and XEN1120 in acute pain expected to initiate in H1 2027 VANCOUVER, BC and BOSTON, MA, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced positive Phase 1 study results and new preclinical data supporting the advancement of XEN1701 and XEN1120 to Phase 2 proof-of-concept studies in acute pain. Data were presented in two poster presentations during the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, taking place October 26–30, 2026 in Bangkok, Thailand.

news source

GlobeNewsWire • Oct 29, 2026

news preview

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).

news source

GlobeNewsWire • Oct 21, 2026

news preview

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.

news source

Zacks Investment Research • Oct 15, 2026

news preview

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.

news source

Newsfile Corp • Sep 29, 2026

news preview

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

Xenon Pharmaceuticals NASDAQ: XENE said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability.

news source

MarketBeat • Sep 27, 2026

news preview

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $XENE--XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law.

news source

Business Wire • Sep 23, 2026

news preview

Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)

Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials -- XENE shares fell as much as 27.6%. NEW YORK, Sept.

news source

PRNewsWire • Sep 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Xenon Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Xenon Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in XENE on M1